Product Information
LEVETIRACETAM 250 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0562 per EA under NDC 64980060412. Its NADAC has been published 113 times since Aug 7, 2024.
FDA first approved this application on Jul 28, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980060412
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVETIRACETAMApproval Type
Generic (ANDA)
FDA Application
ANDA090767FDA Approved
7/28/2010
TE Code
AB
On Market Since
6/10/2024
Pharmacological Classes
Price Statistics
The NADAC for LEVETIRACETAM 250 MG TABLET has been published 113 times since Aug 7, 2024, and over the history we have for it it has risen 13.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0562 per EA |
|---|---|
| All-time high | $0.0645 (Sep 11, 2024) |
| All-time low | $0.0454 (Nov 20, 2024) |
| 52-week high | $0.0605 |
| 52-week low | $0.0562 |
| Median price | $0.0599 |
| Average price | $0.0588 |
| Largest weekly change | +30.7% (Aug 21, 2024) |
| Weeks tracked | 113 |
| Tracking since | Aug 7, 2024 |
Generic Alternatives
The matcher finds 17 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levetiracetam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVETIRACETAM 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVETIRACETAM 250 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0562 per EA (NDC 64980060412), effective Sep 30, 2026.
How has the price of LEVETIRACETAM 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVETIRACETAM 250 MG TABLET has risen 13.8%. It has been tracked across 113 weekly CMS publications since Aug 7, 2024.
What are the highest and lowest recorded NADAC prices for LEVETIRACETAM 250 MG TABLET?
Since Aug 7, 2024, the NADAC for LEVETIRACETAM 250 MG TABLET has ranged from a low of $0.0454 (Nov 20, 2024) to a high of $0.0645 (Sep 11, 2024), with a median of $0.0599 per EA.
Are there cheaper alternatives to LEVETIRACETAM 250 MG TABLET?
Yes. 17 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVETIRACETAM 250 MG TABLET, is $0.0494 per EA — about 12% below LEVETIRACETAM 250 MG TABLET.
Who manufactures LEVETIRACETAM 250 MG TABLET?
LEVETIRACETAM 250 MG TABLET (NDC 64980060412) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.